Jian Gao’s in vivo research185 shows that the SHP2 inhibitor SHP099 targets SHP-2, regulating the STING pathway and boosting type I IFNs, thus remodeling the TME and overcoming tumor resistance. Here, PTPN11 is linked to neoplasm.